333 related articles for article (PubMed ID: 24636089)
1. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease.
Milara J; Lluch J; Almudever P; Freire J; Xiaozhong Q; Cortijo J
J Allergy Clin Immunol; 2014 Aug; 134(2):314-22. PubMed ID: 24636089
[TBL] [Abstract][Full Text] [Related]
2. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist.
Milara J; Morell A; Ballester B; Sanz C; Freire J; Qian X; Alonso-Garcia M; Morcillo E; Cortijo J
Respir Res; 2015 Feb; 16(1):12. PubMed ID: 25652132
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells.
Victoni T; Gleonnec F; Lanzetti M; Tenor H; Valença S; Porto LC; Lagente V; Boichot E
PLoS One; 2014; 9(1):e85243. PubMed ID: 24416369
[TBL] [Abstract][Full Text] [Related]
4. Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Totani L; Amore C; Di Santo A; Dell'Elba G; Piccoli A; Martelli N; Tenor H; Beume R; Evangelista V
J Thromb Haemost; 2016 Jan; 14(1):191-204. PubMed ID: 26484898
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast N-Oxide in Combination with Formoterol Enhances the Antiinflammatory Effect of Dexamethasone in Airway Smooth Muscle Cells.
Patel BS; Rahman MM; Baehring G; Xenaki D; Tang FS; Oliver BG; Ammit AJ
Am J Respir Cell Mol Biol; 2017 Apr; 56(4):532-538. PubMed ID: 27997807
[TBL] [Abstract][Full Text] [Related]
6. Future treatment in patients with chronic obstructive pulmonary disease: to reverse or not to reverse steroid resistance-that is the question.
Koenderman L; Chilvers ER
J Allergy Clin Immunol; 2014 Aug; 134(2):323-4. PubMed ID: 24934274
[No Abstract] [Full Text] [Related]
7. Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients.
Milara J; Cervera A; de Diego A; Sanz C; Juan G; Gavaldà A; Miralpeix M; Morcillo E; Cortijo J
Respir Res; 2016 Nov; 17(1):145. PubMed ID: 27825347
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of PDE4 and PI3Kδ modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease.
Dinavahi SS; Nyayapathy S; Perumal Y; Dharmarajan S; Viswanadha S
Drug Res (Stuttg); 2014 Apr; 64(4):214-9. PubMed ID: 24105104
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
Milara J; Peiró T; Serrano A; Guijarro R; Zaragozá C; Tenor H; Cortijo J
Pulm Pharmacol Ther; 2014 Aug; 28(2):138-48. PubMed ID: 24525294
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
Reddy AT; Lakshmi SP; Banno A; Reddy RC
Int J Chron Obstruct Pulmon Dis; 2020; 15():125-134. PubMed ID: 32021151
[TBL] [Abstract][Full Text] [Related]
11. Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.
Dunne AE; Kawamatawong T; Fenwick PS; Davies CM; Tullett H; Barnes PJ; Donnelly LE
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):445-453. PubMed ID: 30395484
[TBL] [Abstract][Full Text] [Related]
12. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Tannheimer SL; Sorensen EA; Haran AC; Mansfield CN; Wright CD; Salmon M
Pulm Pharmacol Ther; 2012 Apr; 25(2):178-84. PubMed ID: 22306235
[TBL] [Abstract][Full Text] [Related]
13. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
14. The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia.
Barreiro E; Puig-Vilanova E; Salazar-Degracia A; Pascual-Guardia S; Casadevall C; Gea J
J Appl Physiol (1985); 2018 Aug; 125(2):287-303. PubMed ID: 29648516
[TBL] [Abstract][Full Text] [Related]
15. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.
To Y; Ito K; Kizawa Y; Failla M; Ito M; Kusama T; Elliott WM; Hogg JC; Adcock IM; Barnes PJ
Am J Respir Crit Care Med; 2010 Oct; 182(7):897-904. PubMed ID: 20224070
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin Increases the Ability of Roflumilast N-oxide to Inhibit Cigarette Smoke-Induced Epithelial to Mesenchymal Transition in Well-differentiated Human Bronchial Epithelial Cells in vitro.
Milara J; Peiró T; Serrano A; Artigues E; Aparicio J; Tenor H; Sanz C; Cortijo J
COPD; 2015 Jun; 12(3):320-31. PubMed ID: 25207459
[TBL] [Abstract][Full Text] [Related]
17. Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD.
Khorasani N; Baker J; Johnson M; Chung KF; Bhavsar PK
Int J Chron Obstruct Pulmon Dis; 2015; 10():283-91. PubMed ID: 25678784
[TBL] [Abstract][Full Text] [Related]
18. The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils.
Gupta V; Khan A; Higham A; Lemon J; Sriskantharajah S; Amour A; Hessel EM; Southworth T; Singh D
Int Immunopharmacol; 2016 Jun; 35():155-162. PubMed ID: 27049289
[TBL] [Abstract][Full Text] [Related]
19. MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease.
Milara J; Díaz-Platas L; Contreras S; Ribera P; Roger I; Ballester B; Montero P; Cogolludo Á; Morcillo E; Cortijo J
Respir Res; 2018 Nov; 19(1):226. PubMed ID: 30458870
[TBL] [Abstract][Full Text] [Related]
20. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition.
Kobayashi Y; Wada H; Rossios C; Takagi D; Charron C; Barnes PJ; Ito K
Br J Pharmacol; 2013 Jul; 169(5):1024-34. PubMed ID: 23758162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
